Approach to Hodgkin's lymphoma in the new millennium

Hematological Oncology

Volumn 20, Issue 1, 2002, Pages 1-15

  Fung, Henry C ^a   Nademanee, Auayporn P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Hodgkin's lymphoma; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LEUKEMIA; MORBIDITY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; TREATMENT FAILURE; VINBLASTINE;

EID: 0036213236     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.683     Document Type: Review

References (55)

1. Epidemiologic patterns of Hodgkin's disease
2. Geographic pathology of lymphoreticular tumors: Summary of survey from the geographic pathology committee of the International Union Against Cancer
3. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study
4. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report
5. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting
6. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
7. Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group
8. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
9. A prognostic score for pateints with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
10. Three cycles of MOPP/ABV (M/A) hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin's disease: Preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients
11. MOPP/ABV vs ABVD for advanced Hodgkin's disease: A preliminary report of CALGB 8952 (with SWOG, ECOG, and NCIC)
12. Improved outcome in British Columbia with optimized combined modality treatment for early stage Hodgkin's Lymphoma
13. MOPP/ABV (M/A) hybrid and irradiation in unfavorable supradiaphragm clinical stages (CS) I-II Hodgkin's disease: Comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8U randomized trial in 995 patients
14. Subtotal nodal versus involved involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease
15. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease
16. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: 10-Year results of the Paris-Ouest-France 81/12 trial, including 262 patients
17. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492
18. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
19. Twenty years of MOPP therapy for Hodgkin's disease
20. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
21. Alternating non-cross- resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results
22. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
23. MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease
24. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial
25. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease
26. BEACOPP chemotherapy for advanced Hodgkin's disease is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results
27. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease
28. Prognostic factors for patients relapsing after radiotherapy for early- stage Hodgkin's disease
29. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
30. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate -stage Hodgkin's disease
31. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse
32. Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience
33. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
34. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial
35. High-dose therapy followed by hematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: Final results of a randomized GHSG and EBMT trial (HD- RI)
36. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
37. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
38. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
39. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
40. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients
41. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
42. What is the optimal time for autologous stem cell transplantation for patients with recurrent Hodgkin's disease who have a long initial remission (interval from 1st CR to relapse > 1 year)
43. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
44. High dose therapy followed by autologous stem cell transplantation for patients with primary refractory Hodgkin's disease: Evaluation of prognostic factors
45. Management strategies for the hard-to-mobilize patient
46. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
47. Long-term survival in Hodgkin's disease
48. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome
49. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease
50. Autologous stem cell transplantation for patients with poor risk Hodgkin's disease treated with a total body irradiation based preparative regimen with or without involved field irradiation: The impact of FTBI and IF-RT on the transplant outcome
51. Efficacy and toxicity of CCNU-based high dose chemotherapy followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
52. Intensified cytoreduction with high dose melphalan and stem cell rescue followed by a second high dose therapy and autologous stem cell transplant for patients with primary refractory or poor risk Hodgkin's lymphoma
53. Ki-4(scFv)-ETA, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
54. Molecular basis of targeted chemotherapy: Novel concepts with special reference to the treatment of Hodgkin's disease
55. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease